Regeneron Pharmaceuticals (REGN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

REGN Regeneron Pharmaceuticals

Watchlist

1150.190
+11.380+1.00%

Close Sep 19 16:00 ET

1150.190
0.0000.00%

Post 20:01 ET

126.79BMarket Cap30.45P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

The Best Biotech Plays Outside the GLP-1 Weight-loss Market
Yahoo Finance17:07 ET
Will Rate Cuts Boost the Stock Market? A Global Equity Investment Guide
Moomoo News GlobalSep 19 08:24 ET · Editors' Picks
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,282
Moomoo NewsSep 17 07:34 ET · Ratings
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,300
Moomoo NewsSep 17 07:34 ET · Ratings
BofA Securities Initiates Regeneron Pharmaceuticals(REGN.US) With Sell Rating, Announces Target Price $805
Moomoo NewsSep 17 05:33 ET · Ratings
Express News | Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $1015 Price Target
BenzingaSep 16 12:59 ET

Comments

Moomoo News Global

15 hours ago

Columns Will Rate Cuts Boost the Stock Market? A Global Equity Investment Guide

The Federal Reserve on Wednesday implemented its first rate cut in over four years, reducing the benchmark rate by 50 basis points to a range of 4.75%-5%.
The move surpassed Wall Street's expectations. Analysts had generally anticipated a 25 basis point cut, while the futures market had priced in a 61% probability of a 50 basis point cut and a 39% probability of a 25 basis point reduction.
Market Response to First Rate Cut
St...

Aggressive 50bp rate cut. How would you update your assets?

Meltyy

Sep 10 04:37

📅 FDA PDUFA & AdCom Update…

📣 ITRM AdCom 9/9 meeting ongoing 🚗
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...

Analysts Notebook

Aug 27 06:33

Columns Ready for Fed Rate Cuts? Biotech's Potential to Watch

The Federal Reserve appears poised to cut interest rates later this year. While the broader stock market might breathe a sigh of relief, certain sectors could be more significantly impacted than others. Biotechnology could be one of those sectors - at least, that's what Morgan Stanley believes.
In 2024, biotech stocks had a slow start, with the S&P Biotechnology Select Industry Index returning just under 4% in the first six months, compared to...